Nicorandil added to usual rheumatoid arthritis medicines to lower artery plaque risk
Tests nicorandil alongside usual medicines in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07800351, who can take part
Where in Egypt
- Rheumatology, Rehabilitation and Physical Medicine department -Tanta university hospitalsTanta, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT07800351
- Record updated
- 11 September 2026
- Original description
The goal of this clinical trial is to learn about the effects of adding nicorandil to conventional Disease-Modifying Antirheumatic Drugs(DMARDs) in treatment of patients with rheumatoid arthritis. The main questions it aims to answer are:Read full original descriptionShow less
Effect of Nicorandil on Atherosclerosis Risk in Patients With Rheumatoid Arthritis: A Randomized Controlled Clinical Trial.
The goal of this clinical trial is to learn about the effects of adding nicorandil to conventional Disease-Modifying Antirheumatic Drugs(DMARDs) in treatment of patients with rheumatoid arthritis. The main questions it aims to answer are:
Does adding nicorandil to conventional DMARDs in treatment of patients with rheumatoid arthritis reduce the risk of plaque buildup in arteries (atherosclerosis) ? and What medical problems may participants have when taking nicorandil ?
Participants will:
Take nicorandil added to DMARDs or DMARDs only for 3 months patient will be assessed at baseline and 3 months after for disease activity and risk of plaque formation over vascular wall
Keep a diary of their symptoms and possible side effects
Inclusion: Adults aged 18-70 years, diagnosed with rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria; Receiving conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy for at least 3 months; Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion: RA patients receiving biological DMARDs (bDMARDs); Patients on lipid-lowering drugs (e.g., statins, fibrates); Currently participating in or has participated in a study of an investigational agent or device within 30 days prior to screening; Chronic autoimmune disease other than rheumatoid arthritis; Patients with metabolic or endocrine disease (e.g., diabetes mellitus, dyslipidemia); Severe renal or hepatic impairment; Any history of malignancy; Current acute or chronic infection; Known hypersensitivity or allergy to nicorandil or any of its components; Current pregnancy or breastfeeding.